The Library
Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial
Tools
Tools
Tools
Smith, F. Gao (Fang Gao), Perkins, Gavin D., Gates, Simon, Young, Duncan, McAuley, Daniel F., Tunnicliffe, William, Khan, Z. (Zahid) and Lamb, S. E. (Sallie E.) (2012) Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. The Lancet, Vol. 379 (No. 9812). pp. 229-235. doi:10.1016/S0140-6736(11)61623-1 ISSN 01406736.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1016/S0140-6736(11)61623-1
Abstract
Background
In a previous randomised controlled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in patients with acute respiratory distress syndrome (ARDS) reduced extravascular lung water and plateau airway pressure. We assessed the effects of this intervention on mortality in patients with ARDS.
Methods
We did a multicentre, placebo-controlled, parallel-group, randomised trial at 46 UK intensive-care units between December, 2006, and March, 2010. Intubated and mechanically ventilated patients (aged ≥16 years) within 72 h of ARDS onset were randomly assigned to receive either salbutamol (15 μg/kg ideal bodyweight per h) or placebo for up to 7 days. Randomisation was done by a central telephone or web-based randomisation service with minmisation by centre, pressure of arterial oxygen to fractional inspired oxygen concentration (PaO2/FIO2) ratio, and age. All participants, caregivers, and investigators were masked to group allocation. The primary outcome was death within 28 days of randomisation. Analysis was by intention-to-treat. This trial is registered, ISRCTN38366450 and EudraCT number 2006-002647-86.
Findings
We randomly assigned 162 patients to the salbutamol group and 164 to the placebo group. One patient in each group withdrew consent. Recruitment was stopped after the second interim analysis because of safety concerns. Salbutamol increased 28-day mortality (55 [34%] of 161 patients died in the salbutamol group vs 38 (23%) of 163 in the placebo group; risk ratio [RR] 1·47, 95% CI 1·03—2·08).
Interpretation
Treatment with intravenous salbutamol early in the course of ARDS was poorly tolerated. Treatment is unlikely to be beneficial, and could worsen outcomes. Routine use of β-2 agonist treatment in ventilated patients with this disorder cannot be recommended.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine |
||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||
| Library of Congress Subject Headings (LCSH): | Respiratory distress syndrome, Adult -- Treatment, Clinical trials, Beta adrenoceptors -- Therapeutic use, Adrenergic beta agonists, Intravenous therapy | ||||
| Journal or Publication Title: | The Lancet | ||||
| Publisher: | Elsevier BV | ||||
| ISSN: | 01406736 | ||||
| Official Date: | 2012 | ||||
| Dates: |
|
||||
| Volume: | Vol. 379 | ||||
| Number: | No. 9812 | ||||
| Page Range: | pp. 229-235 | ||||
| DOI: | 10.1016/S0140-6736(11)61623-1 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | Medical Research Council (Great Britain), Great Britain. Dept. of Health, Intensive Care Society (Great Britain), National Institute for Health Research (Great Britain) (NIHR) |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
